Searched for: subject:"Double%5C-Blind%5C%2BMethod"
(1 - 9 of 9)
document
Ceconi, C. (author), Fox, K.M. (author), Remme, W.J. (author), Simoons, M.L. (author), Deckers, J.W. (author), Bertrand, M. (author), Parrinello, G. (author), Kluft, C. (author), Blann, A. (author), Cokkinos, D. (author), Ferrari, R. (author), TNO Kwaliteit van Leven (author)
The PERTINENT study measured biomarkers of atherosclerosis and thrombosis in a stable coronary artery disease population from EUROPA receiving ACE inhibition with perindopril 8 mg/day or placebo. Biomarkers of inflammation, C-reactive protein (CRP), fibrinogen, and tumor necrosis factor-alpha (TNF-α), and a biomarker of thrombosis, d-dimer, were...
article 2009
document
Hellgren, M. (author), Conard, J. (author), Norris, L. (author), Kluft, C. (author), TNO Kwaliteit van Leven (author)
Objective: To study cardiovascular risk markers in women taking estradiol/trimegestone or estradiol/dydrogesterone. Design: Multicenter, randomized, prospective, double-blind study of 184 healthy post-menopausal women randomized to 6 cycles of either estradiol (2 mg) + trimegestone (0.5 mg) (T-group) or estradiol (2 mg) + dydrogesterone (10 mg) ...
article 2009
document
van de Ree, M.A. (author), de Maat, M.P. (author), Kluft, C. (author), Meinders, A.E. (author), Princen, H.M. (author), Huisman, M.V. (author), Gaubius Instituut TNO (author)
BACKGROUND: Patients with Type 2 diabetes mellitus have increased levels of hemostatic risk variables for cardiovascular disease, such as fibrinogen, von Willebrand factor (VWF), factor (F)VIIa, d-dimer and plasminogen activator inhibitor-1 (PAI-1). OBJECTIVES: To evaluate the effect of aggressive vs. standard dose atorvastatin on hemostatic...
article 2003
document
de Valk-de Roo, G.W. (author), Stehouwer, C.D.A. (author), Meijer, P. (author), Mijatovic, V. (author), Kluft, C. (author), Kenemans, P. (author), Cohen, F. (author), Watts, S. (author), Netelenbos, C. (author), Gaubius instituut TNO (author)
Currently raloxifene, a selective estrogen receptor modulator, is being investigated as a potential alternative for postmenopausal hormone replacement to prevent osteoporosis and cardiovascular disease. We compared the 2-year effects of raloxifene on a wide range of cardiovascular risk factors with those of placebo and conjugated equine...
article 1999
document
de Maat, M.P.M. (author), Kastelein, J.J.P. (author), Jukema, J.W. (author), Zwinderman, A.H. (author), Jansen, H. (author), Groenemeier, B. (author), Bruschke, A.V.G. (author), Kluft, C. (author), Gaubius instituut TNO (author)
Increased plasma fibrinogen levels have been identified as a risk indicator for myocardial infarction, stroke, and thrombosis. Both environmental and genetic factors make an important contribution to plasma fibrinogen levels in humans. In the present study we evaluated, in patients with serum cholesterol levels between 4 and 8 mmol/L, the...
article 1998
document
Myrup, B. (author), Jensen, T. (author), Gram, J. (author), Kluft, C. (author), Jespersen, J. (author), Deckert, T. (author), Gaubius Instituut TNO (author)
OBJECTIVE - The high risk for cardiovascular disease in IDDM patients with nephropathy may be mediated by abnormal function of the vascular wall. We investigated whether heparin was able to modulate markers of vascular wall and hemostatic function in patients with incipient nephropathy. RESEARCH DESIGN AND METHODS - Thirty-five IDDM patients...
article 1997
document
Brussaard, H.E. (author), Gevers Leuven, J.A. (author), Frölich, M. (author), Kluft, C. (author), Krans, H.M.J. (author), Gaubius Instituut TNO (author)
Oestrogen replacement therapy is associated with a decreased risk of cardiovascular disease in postmenopausal women. Patients with non-insulin- dependent diabetes mellitus (NIDDM) have an increased cardiovascular risk. However, oestrogen replacement therapy is only reluctantly prescribed for patients with NIDDM. In a double blind randomized...
article 1997
document
Kockx, M. (author), de Maat, M.P.M. (author), Knipscheer, H.C. (author), Kastelein, J.P. (author), Kluft, C. (author), Princen, H.M.G. (author), Kooistra, T. (author), Gaubius Instituut TNO (author)
Evaluation of fibrate treatment in humans has focused primarily on its anti-lipidaemic effects. A potentially favourable haemostasis-modulating activity of fibrates has also been recognized but the data are not consistent. We sought to learn more about this variability by examining the effects of gemfibrozil and ciprofibrate on plasma levels of...
article 1997
document
de Maat, M.P.M. (author), Arnold, A.E.R. (author), van Buuren, S. (author), Wilson, J.H.P. (author), Kluft, C. (author), Gaubius Instituut TNO (author)
Elevated plasma fibrinogen levels are associated with an increased risk for cardiac events. Ticlopidine is a drug that inhibits the ADP-induced aggregation of blood platelets and it also has been described that ticlopidine can decrease the plasma fibrinogen level in patients with vascular diseases. The mechanism of this decrease has not yet been...
article 1996
Searched for: subject:"Double%5C-Blind%5C%2BMethod"
(1 - 9 of 9)